TFDP2-PDK3轴驱动糖代谢重编程促进鼻咽癌放疗抵抗
该研究整合8例鼻咽癌单细胞RNA测序数据与放疗抵抗细胞模型mRNA测序数据,识别TFDP2在放疗抵抗中的核心作用。体内外实验证实TFDP2高表达增强放疗抵抗并预测更差临床结局,机制上TFDP2通过激活PDK3转录使代谢从氧化磷酸化转向糖酵解。
要点
- TFDP2高表达增强鼻咽癌放疗抵抗并预测更差临床结局
- TFDP2通过激活PDK3转录重编程代谢为糖酵解
- TFDP2-PDK3轴是改善鼻咽癌放疗疗效的潜在治疗靶点
核心结论
- TFDP2介导的代谢重编程是鼻咽癌放疗抵抗的关键机制,提供潜在治疗靶点。
研究设计与样本
- 整合8例局部鼻咽癌样本单细胞RNA测序数据与放疗抵抗细胞模型mRNA测序数据识别TFDP2。
- 通过体内外实验验证TFDP2在放疗抵抗中的关键作用。
- 对TFDP2沉默细胞行转录组测序及生物信息学分析探索机制。
- 采用代谢指标检测、免疫荧光、免疫组化、ChIP-qPCR和双荧光素酶报告实验阐明分子机制。
主要发现
- TFDP2在鼻咽癌放疗抵抗中起关键作用,其高表达增强放疗抵抗并预测更差临床结局。
- TFDP2通过激活PDK3转录,使代谢从氧化磷酸化转向糖酵解。
临床怎么用
- TFDP2高表达可提示鼻咽癌患者放疗抵抗风险及更差临床结局。
- 靶向TFDP2-PDK3轴可能成为改善鼻咽癌放疗疗效的潜在策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although nasopharyngeal carcinoma (NPC) is highly radiosensitive, tumor radioresistance inevitably leads to local recurrence and distant metastasis, posing a major clinical challenge for NPC treatment. MATERIALS AND METHODS: By integrating single-cell RNA sequencing data from eight local NPC samples, mRNA sequencing data from pre-established radioresistant cell models, and phenotype-associated gene sets shared across heterogeneous tumor cells, we identified the potential central role of Transcription Factor Dimerization Partner 2 (TFDP2) in radioresistance. After demonstrating the critical role of TFDP2 in radioresistance through comprehensive in vitro and in vivo experiments, we performed transcriptome sequencing on TFDP2-silenced cells and conducted bioinformatic analysis to explore the potential mechanism. Finally, using a series of functional assays, including examination of key metabolic indicators, immunofluorescence, immunohistochemistry, chromatin immunoprecipitation (ChIP)-qPCR, and dual-luciferase reporter assays, we elucidated the precise molecular mechanism by which TFDP2 mediates radioresistance. RESULTS: TFDP2 plays a pivotal role in the process of radioresistance in NPC: its elevated expression not only enhances radiation resistance but also predicts worse clinical outcomes in publicly available NPC cohorts. Mechanistically, TFDP2 promotes radioresistance by activating Pyruvate Dehydrogenase Kinase Isozyme 3 (PDK3) transcription, which reprograms metabolism from oxidative phosphorylation to glycolysis. CONCLUSIONS: This work establishes TFDP2-mediated metabolic reprogramming as a critical mechanism of radioresistance, offering mechanistic insights and a potential therapeutic target for improving radiotherapy outcomes in NPC.
引用
- Yang Q, Fang J, Chen C, et al. The TFDP2-PDK3 axis drives glucose metabolic reprogramming to promote radioresistance in nasopharyngeal carcinoma. Radiother Oncol. 2026. PMID: 42520978. doi:10.1016/j.radonc.2026.111708
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。